Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for Painful Chronic TMD
NCT05162027Phase 2Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2022
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in temporomandibular disorders (TMD) comparing Erenumab-aooe with Placebo (2 arms). Primary endpoint: Reduction in Monthly Average Pain Score at 16 weeks. Started May 2022; status: terminated.
02
Drugs
erenumab
03
Conditions
temporomandibular disorders (TMD)
Beyond the preview
Go deeper on NCT05162027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162027.